Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Fig. 3

VEGF-specific IgG subclasses between weeks 6–12, 16–48, 49–96 and 97–144. The study was made for the available serum samples classified as positive for VEGF-specific IgG antibodies. “n” represents the number of the available serum samples. Terms “non-detectable”, “detectable” and “predominant” are detailed in Methods

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us